Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
AML
DRUG: Glivec|DRUG: Mitoxantrone|DRUG: Topotecan|DRUG: AraC
To show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.